Development and validation of a sensitive HPLC-MS/MS-ESI method for determination of febuxostat: Application to pharmacokinetic study

Current Analytical Chemistry

Volumn 10, Issue 4, 2014, Pages 528-536

  Choudhury, Hira ^a   Gorain, Bapi ^a   Das, Ayan ^a   Ghosh, Balaram ^b   Pal, Tapan ^a  

^a JADAVPUR UNIVERSITY   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Bioanalytical method; Febuxostat; Human plasma; LC MS MS; Pharmacokinetic study; Validation

Indexed keywords

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; PLASMA (HUMAN); POSITIVE IONS;

BIOANALYTICAL METHODS; FEBUXOSTAT; HPLC-MS-MS; HUMAN PLASMAS; LC-MS-MS; LC.MS/MS; PHARMACOKINETIC STUDIES; SENSITIVE ASSAY METHOD; SIMPLE++; VALIDATION;

ELECTROSPRAY IONIZATION;

EID: 84904761996     PISSN: 15734110     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341101004140701115811     Document Type: Article

References (19)

1. Highlights of prescribing information of Uloric (febuxostat) tablet for oral use. http://www. accessdata. fda. gov/drugsatfda_docs/label/2011/021856s003lbl. pdf (Accessed March 22, 2012).
2. Terkeltaub, R. A. Clinical practice. Gout. N. Engl. J. Med., 2003, 349, 1647-1655.
3. Hyperuricemia in Medscape Reference, Drugs, disease and Procedures. http://emedicine. medscape. com/article/241767-overview# a0199 (Accessed March 15, 2012).
4. Mayer, M. D.; Khosravan, R.; Vernillet, L.; Wu, J. T.; Ridge, N. J.; Mulford, D. J. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am. J. Ther., 2005, 12, 22-34.
5. Arromdee, E.; Michet, C. J.; Crowson, C. S.; O'Fallon, W. M.; Gabriel, S. E. Epidemiology of gout: is the incidence rising? J. Rheumatol., 2005, 29, 2403-2406.
6. Love, B. L.; Barrons, R.; Veverka, A.; Snider, K. M. Urate-Lowering Therapy for Gout: Focus on Febuxostat. Pharmacotherapy, 2010, 30(6), 594-608.
7. Ifudu, O.; Tan, C. C.; Dulin, A. L.; Delano, B. G.; Friedman EA. Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. Am. J. Kidney Dis., 1994, 23, 347-51.
8. Foreman, J. W.; Yudkoff, M. Familial hyperuricemia and renal insufficiency. Child Nephrol. Urol., 1990, 10, 115-118.
9. Van, G. W.; Koorker, C. J.; Mees, C. J. D. An unusual form of renal disease associated with gout and hypertension. J. Clin. Pathol., 1971, 24, 254-259.
10. Massari, P. U.; Hsu, C. H.; Barnes, R. V.; Fox, I. H.; Gikas, P. W.; Weller, J. M. Familial hyperuricemia and renal disease. J. Clin. Pathol., 1980, 140(5), 680-684.
11. Lukram, O.; Parmar, S.; Hande, A. Determination of febuxostat in human plasma using ultra-performance liquid chromatography tandem mass spectrometry. Drug Test. Anal., 2012, DOI 10. 1002/dta. 420.
12. Wang, H.; Deng, P.; Chen, X.; Guo, L.; Zhong, D. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in human plasma. Biomed. Chromatogr., 2012 (DOI 10. 1002/bmc. 2744).
13. Sengupta, P.; Sarkar, A. K.; Bhaumik, U.; Chatterjee, B.; Roy, B.; Chakraborty, U. S.; Pal, T. K. Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application. Biomed. Chromatogr., 2010, 24, 1342-1349.
14. Viswanathan, C. T.; Bansal, S.; Booth, B.; DeStefano, A. J.; Rose, M. J.; Sailstad, J.; Shah, V. P.; Skelly, J. P.; Swann, P. G.; Weiner, R. Workshop/Conference Report Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. AAPS J., 2007, 9(1), Article 4.
15. Bansal, S.; DeStefano, A. Key elements of bioanalytical method validation for small molecule. AAPS J., 2007, 9(1), Article 11. E109-E114. S.
16. Food and Drug Administration of the United States (May 2001). Guidance for industry. Bioanalytical Method Validation. http://www. fda. gov/cder/guidance/index. html (Accessed: November 12, 2011).
17. King, R.; Bonfiglio, R.; Fernandez-Metzler, C.; Miller-Stein, C.; Olah, T. Mechanistic investigation of ionization suppression in electrospray ionization. J. Am. Soc. Mass Spectrom., 2000, 11, 942-950.
18. Mei, H.; Hsieh, Y.; Nardo, C.; Xu, X.; Wang, S.; Ng, K.; Korfmacher, W. A. Investigation of matrix effects in bioanalytical high-performance liquid chromatography/tandem mass spectrometric assays: application to drug discovery. Rapid Commun. Mass Spectrom., 2003, 17(1), 97-103.
19. Dams, R.; Huestis, M. A.; Lambert, W. E.; Murphy, C. M. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: Influence of ionization type, sample preparation, and biofluid. J. Am. Soc. Mass Spectrom., 2003, 14, 1290-1294.